ANO1 and prostate carcinoma: For instance, Duvvuri et al. [2] observed a significant association between TMEM16A levels and overall survival in head and neck cancers; however, such findings have not been consistently replicated in prostate cancer, which raises concerns about the broader applicability of TMEM16A as a biomarker across diverse malignancies.